Welcome to our dedicated page for Solana news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana stock.
Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Helius Medical Technologies has received a significant boost with the issuance of U.S. Patent No. 11,197,994, enhancing its Portable Neuromodulation Stimulator (PoNS) device. This patent allows for wired communication between the mouthpiece and the controller, paving the way for next-generation PoNS therapy. Currently, Helius holds 34 U.S. and 46 foreign patents, and PoNS is approved for treating gait deficits in MS patients in the U.S., while authorized for use in Canada and Australia for similar conditions. The advancements position Helius strongly in the neurotech market.
Helius Medical Technologies announced that Dr. Antonella Favit-Van Pelt will present at the 4th International Brain Stimulation Conference from December 6-9, 2021, in Charleston, S.C. She will discuss the research leading to FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis. Helius received FDA marketing authorization for its Portable Neuromodulation Stimulator (PoNS) in March 2021 and Breakthrough Designation for stroke treatment in August 2021. This symposium highlights innovative brain stimulation treatments advancing patient care.
Helius Medical Technologies (Nasdaq: HSDT) announced participation in 1x1 meetings at the 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021. CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will represent the company. Interested investors should contact their Craig-Hallum representative for meeting arrangements.
Helius focuses on neurologic wellness using its non-implantable technologies, including the Portable Neuromodulation Stimulator (PoNS), aimed at improving lives affected by neurologic diseases.
Helius Medical Technologies, Inc. (Nasdaq: HSDT) closed its underwritten public offering of 1,385,031 shares of Class A common stock at $8.00 per share, generating approximately $11.1 million in gross proceeds. This includes the full exercise of the underwriter's over-allotment option. The company will utilize the net proceeds for funding operations, working capital, and other corporate purposes. The offering was conducted under a shelf registration statement declared effective by the SEC in 2020.
Helius Medical Technologies (Nasdaq:HSDT) reported its Q3 2021 financial results, with revenue of $109K, down from $131K in Q3 2020. Operating loss increased to $4.4M, compared to $3.7M in the prior year. The net loss was $4.7M, or $(2.01) per share. Helius received FDA Breakthrough Designation for its PoNS device for stroke-related gait deficits and launched a Therapeutic Experience Program with NYU. The company secured a $15 million equity line of credit and announced a $9.6 million public offering. Cash balance stood at $4.7 million as of Sept 30, 2021.
Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced a public offering of 1,204,375 shares of common stock at $8.00 per share, aiming to raise approximately $9.6 million in gross proceeds. The offering will close around November 12, 2021, subject to customary conditions. The company plans to use the net proceeds for operations, working capital, and general corporate purposes. Ladenburg Thalmann & Co. Inc. serves as the sole book-running manager for the offering, which is conducted under an effective shelf registration statement.
Helius Medical Technologies (HSDT) announced a proposed underwritten public offering of its common stock. The company will sell all shares, with a potential additional 15% option for the underwriter. Proceeds from the offering will be directed towards funding operations, working capital, and general corporate purposes. This offering is contingent on market conditions and follows a shelf registration statement effective since February 6, 2020. Ladenburg Thalmann & Co. Inc. is the sole book-running manager for this offering.
Helius Medical Technologies (Nasdaq: HSDT) has launched its Therapeutic Experience Program (TEP) in partnership with NYU Langone Health to assess adherence to PoNS therapy in patients with multiple sclerosis (MS). The study aims to evaluate the effectiveness of the PoNS device in improving gait deficits, enrolling 50-60 patients across 10-12 Centers of Excellence in the U.S. Enrollment is expected to begin in Q4 2021 and continue through mid-2022. This program is pivotal for understanding the relationship between treatment adherence and therapeutic outcomes in a real-world setting.
Helius Medical Technologies (Nasdaq:HSDT) announced receiving market authorization from the Australian Therapeutic Goods Administration for its PoNS device as a Class IIa medical device. This authorization allows PoNS to be sold in Australia to aid patients in improving balance and gait when used alongside therapeutic exercises. The company is preparing for commercialization in Australia, marking the third country to authorize PoNS, following the U.S. and Canada. CEO Dane C. Andreeff expressed enthusiasm for this development.
Helius Medical Technologies (NASDAQ: HSDT) plans to release its third quarter 2021 financial results on November 10, 2021, after market close. CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will host a conference call at 5:00 PM ET to discuss results and company updates. The Portable Neuromodulation Stimulator (PoNS®), Helius’s first commercial product, aims to assist patients with gait deficits from conditions like multiple sclerosis and traumatic brain injuries. PoNS® is currently authorized in the U.S. and Canada for specific medical uses.